Shouru Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shouru Xue has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Lei Li
Department of Neurology, The Yancheng Clinical College of Xuzhou Medical University, The First People’s Hospital of Yancheng
4 shared publicationsYingchao Ge
Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
4 shared publicationsYongqing Cheng
Department of Neurology, The Yancheng Clinical College of Xuzhou Medical University, The First People’s Hospital of Yancheng
4 shared publications- Guojun He
Department of Neurology, The Yancheng Clinical College of Xuzhou Medical University, The First People’s Hospital of Yancheng, Yancheng, Jiangsu, China
3 shared publications Guomei Shi
Department of Neurology, The Taixing People’s Hospital, Taixing, Jiangsu, People’s Republic of China
3 shared publicationsShuangfei You
Department of Neurology, The Yancheng Clinical College of Xuzhou Medical University, The First People’s Hospital of Yancheng
3 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1748084
Systemic inflammatory index correlates with cerebral small vessel disease in Parkinson’s disease
Background: This study investigates the association between systemic inflammatory indices—specifically, the systemic immune inflammation index (SII) and systemic inflammation response index (SIRI)—and the severity of cerebral small vessel disease (CSVD) in patients with Parkinson’s disease (PD). Methods: A total of 167 patients with primary PD and complete MRI data were included. CSVD severity was assessed using total and modified CSVD burden scores, with patients categorized into two groups: mild (scores 0–1 or 0–2) and moderate–severe (scores 2–4 or 3–6). Logistic and ROC analyses were employed to evaluate the association and discriminative ability of SII and SIRI for CSVD severity. Results: Among 167 patients (59.3% male, mean age 69.6 ± 8.7 years), 91 and 96 were classified with moderate–severe CSVD based on total and modified scores, respectively. Higher SII and SIRI levels, along with a greater proportion of hypertension, were observed in the moderate–severe CSVD group. Spearman analysis indicated SII weakly correlated with both CSVD scores (total: r = 0.224, p = 0.004; modified: r = 0.155, p = 0.046), while SIRI showed a weak correlation with the total score only ( r = 0.179, p = 0.021). After adjusting for covariates, logistic regression showed the highest tertiles of SII and SIRI were significantly associated with moderate–severe CSVD, whether using the total score (T3 vs. T1: OR 2.919, 95% CI 1.191–7.153 for SII; OR 4.295, 95% CI 1.681–10.973 for SIRI) or the modified score (T3 vs. T1: OR 4.196, 95% CI 1.705–10.327 for SII; OR 3.303, 95% CI 1.326–8.226 for SIRI). Conclusion: Although their individual discriminatory abilities are limited, elevated SII and SIRI are independently associated with more severe CSVD in PD patients.
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1748084
Open AccessSystemic inflammatory index correlates with cerebral small vessel disease in Parkinson’s disease
Background: This study investigates the association between systemic inflammatory indices—specifically, the systemic immune inflammation index (SII) and systemic inflammation response index (SIRI)—and the severity of cerebral small vessel disease (CSVD) in patients with Parkinson’s disease (PD). Methods: A total of 167 patients with primary PD and complete MRI data were included. CSVD severity was assessed using total and modified CSVD burden scores, with patients categorized into two groups: mild (scores 0–1 or 0–2) and moderate–severe (scores 2–4 or 3–6). Logistic and ROC analyses were employed to evaluate the association and discriminative ability of SII and SIRI for CSVD severity. Results: Among 167 patients (59.3% male, mean age 69.6 ± 8.7 years), 91 and 96 were classified with moderate–severe CSVD based on total and modified scores, respectively. Higher SII and SIRI levels, along with a greater proportion of hypertension, were observed in the moderate–severe CSVD group. Spearman analysis indicated SII weakly correlated with both CSVD scores (total: r = 0.224, p = 0.004; modified: r = 0.155, p = 0.046), while SIRI showed a weak correlation with the total score only ( r = 0.179, p = 0.021). After adjusting for covariates, logistic regression showed the highest tertiles of SII and SIRI were significantly associated with moderate–severe CSVD, whether using the total score (T3 vs. T1: OR 2.919, 95% CI 1.191–7.153 for SII; OR 4.295, 95% CI 1.681–10.973 for SIRI) or the modified score (T3 vs. T1: OR 4.196, 95% CI 1.705–10.327 for SII; OR 3.303, 95% CI 1.326–8.226 for SIRI). Conclusion: Although their individual discriminatory abilities are limited, elevated SII and SIRI are independently associated with more severe CSVD in PD patients.
- Open Access
- 2 December 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17
Correlation between cerebral small vessel disease and postural instability/gait difficulty subtype in Parkinson’s disease patients
Background: Postural instability/gait difficulty (PIGD) subtype in Parkinson’s disease (PD) portends poorer prognosis and limited treatment response. While cerebral small vessel disease (CSVD) is implicated in motor impairment, its specific association with PIGD remains underexplored. This study aims to investigate the correlation between the severity of CSVD and PIGD subtype in PD patients. Methods: This cross-sectional study enrolled 161 PD patients (mean age 71.14 ± 7.04 years). Motor subtyping [postural instability and gait difficulty (PIGD)/tremor-dominant (TD)/intermediate type (IT)] used MDS-UPDRS-derived ratios. CSVD burden was quantified via two validated MRI-based scores: the total CSVD burden score (range 0–4) and modified CSVD burden score (range 0–6). Multivariate logistic regression analysis, which adjusted for age, gender, disease duration, and vascular risk factors, was used to explore the correlation between CSVD burden and PIGD. Results: The prevalence of PIGD was 49.07% ( n = 79). PIGD patients exhibited a significantly higher CSVD burden than the TD and IT groups (total score: 1.84 ± 0.72 vs. 1.4 ± 0.59 vs.1.15 ± 0.49; modified score: 2.55 ± 1.20 vs. 1.85 ± 0.7 vs. 1.75 ± 0.91, both p < 0.001). After full adjustment, each 1-point increase in total CSVD burden score associated with 7.16-fold higher PIGD odds (aOR = 7.16, 95%CI = 1.64–30.82, p = 0.009), and each 1-point increase in modified CSVD burden score associated with 6.03-fold higher PIGD odds (aOR = 6.03, 95%CI = 3.06–11.90, p < 0.001). Conclusion: Global CSVD burden was independently associated with the occurrence of PIGD in PD. CSVD assessment may help identify PD patients at the highest risk for axial motor disability, highlighting the convergence of vascular and neurodegenerative pathologies.
- 2 December 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17
Open AccessCorrelation between cerebral small vessel disease and postural instability/gait difficulty subtype in Parkinson’s disease patients
Background: Postural instability/gait difficulty (PIGD) subtype in Parkinson’s disease (PD) portends poorer prognosis and limited treatment response. While cerebral small vessel disease (CSVD) is implicated in motor impairment, its specific association with PIGD remains underexplored. This study aims to investigate the correlation between the severity of CSVD and PIGD subtype in PD patients. Methods: This cross-sectional study enrolled 161 PD patients (mean age 71.14 ± 7.04 years). Motor subtyping [postural instability and gait difficulty (PIGD)/tremor-dominant (TD)/intermediate type (IT)] used MDS-UPDRS-derived ratios. CSVD burden was quantified via two validated MRI-based scores: the total CSVD burden score (range 0–4) and modified CSVD burden score (range 0–6). Multivariate logistic regression analysis, which adjusted for age, gender, disease duration, and vascular risk factors, was used to explore the correlation between CSVD burden and PIGD. Results: The prevalence of PIGD was 49.07% ( n = 79). PIGD patients exhibited a significantly higher CSVD burden than the TD and IT groups (total score: 1.84 ± 0.72 vs. 1.4 ± 0.59 vs.1.15 ± 0.49; modified score: 2.55 ± 1.20 vs. 1.85 ± 0.7 vs. 1.75 ± 0.91, both p < 0.001). After full adjustment, each 1-point increase in total CSVD burden score associated with 7.16-fold higher PIGD odds (aOR = 7.16, 95%CI = 1.64–30.82, p = 0.009), and each 1-point increase in modified CSVD burden score associated with 6.03-fold higher PIGD odds (aOR = 6.03, 95%CI = 3.06–11.90, p < 0.001). Conclusion: Global CSVD burden was independently associated with the occurrence of PIGD in PD. CSVD assessment may help identify PD patients at the highest risk for axial motor disability, highlighting the convergence of vascular and neurodegenerative pathologies.
- Open Access
- 28 August 2025
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1620118
A high triglyceride-glucose index correlates with cognitive impairment in Parkinson’s disease: a cross-sectional study
Background: Insulin resistance (IR) is proved be involved in the pathophysiology of Parkinson’s disease (PD). As an effective surrogate marker of IR, the correlation between the triglyceride-glucose (TyG) index and PD remains unclear. This cross-sectional study aimed to explore the association between the TyG index and cognitive impairment in PD (PDCI).Methods: Patients with sporadic PD were consecutively enrolled between May 2022 and October 2023. The cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA). The Spearman correlation analysis was used to evaluate the correlation between TyG index and MoCA score, Unified-Parkinson Disease Rating Scale (UPDRS) III and peripheral blood oxidative stress markers, respectively. Logistic regression analysis was performed to explore the correlation between TyG and PDCI and dementia in PD (PDD).Results: A total of 78 patients were enrolled, of whom 50 (64.1%) were diagnosed with PDCI [26 with mild cognitive impairment (MCI) and 24 with PDD]. The TyG index in patients with dementia and MCI were higher than those with normal cognition (9.32 ± 0.43 vs. 8.90 ± 0.47 vs. 8.51 ± 0.46, P < 0.001). The Spearman correlation analysis demonstrated that TyG was negatively correlated with MoCA (r = −0.704, P < 0.001) and superoxide dismutase (r = −0.244, P = 0.031), but positively correlated with UPDRS III (r = 0.246, P = 0.030). Multivariate logistic regression analysis showed that TyG was independently associated with PDCI regardless of whether it was used as a continuous variable (OR = 6.177, 95% CI = 1.590–24.000) or a tertile variable (OR = 5.478, 95% CI = 1.030–29.132). This association persisted after excluding patients with diabetes. The receiver operating characteristic (ROC) analysis suggested that the area under the curve (AUC) of TyG for predicting PDCI was 0.805 (95% CI = 0.707–0.903, P < 0.001).Conclusion: Elevated TyG levels were associated with an increased likelihood of PDCI in patients with PD.
- 28 August 2025
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 19, 1620118
Open AccessA high triglyceride-glucose index correlates with cognitive impairment in Parkinson’s disease: a cross-sectional study
Background: Insulin resistance (IR) is proved be involved in the pathophysiology of Parkinson’s disease (PD). As an effective surrogate marker of IR, the correlation between the triglyceride-glucose (TyG) index and PD remains unclear. This cross-sectional study aimed to explore the association between the TyG index and cognitive impairment in PD (PDCI).Methods: Patients with sporadic PD were consecutively enrolled between May 2022 and October 2023. The cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA). The Spearman correlation analysis was used to evaluate the correlation between TyG index and MoCA score, Unified-Parkinson Disease Rating Scale (UPDRS) III and peripheral blood oxidative stress markers, respectively. Logistic regression analysis was performed to explore the correlation between TyG and PDCI and dementia in PD (PDD).Results: A total of 78 patients were enrolled, of whom 50 (64.1%) were diagnosed with PDCI [26 with mild cognitive impairment (MCI) and 24 with PDD]. The TyG index in patients with dementia and MCI were higher than those with normal cognition (9.32 ± 0.43 vs. 8.90 ± 0.47 vs. 8.51 ± 0.46, P < 0.001). The Spearman correlation analysis demonstrated that TyG was negatively correlated with MoCA (r = −0.704, P < 0.001) and superoxide dismutase (r = −0.244, P = 0.031), but positively correlated with UPDRS III (r = 0.246, P = 0.030). Multivariate logistic regression analysis showed that TyG was independently associated with PDCI regardless of whether it was used as a continuous variable (OR = 6.177, 95% CI = 1.590–24.000) or a tertile variable (OR = 5.478, 95% CI = 1.030–29.132). This association persisted after excluding patients with diabetes. The receiver operating characteristic (ROC) analysis suggested that the area under the curve (AUC) of TyG for predicting PDCI was 0.805 (95% CI = 0.707–0.903, P < 0.001).Conclusion: Elevated TyG levels were associated with an increased likelihood of PDCI in patients with PD.
- Open Access
- 24 January 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1501319
Baseline liver fibrosis-4 score correlates to the progression of anxiety and cognitive impairment in patients with Parkinson’s disease
Background: Non-alcoholic fatty liver disease (NAFLD) or liver fibrosis may share similar pathophysiological features with Parkinson’s disease (PD), yet their correlation was unclear. This study aimed to explore their correlation between PD and liver fibrosis using the fibrosis-4 score (FIB-4) as a surrogate marker.Methods: We analyzed Parkinson’s Progression Markers Initiative (PPMI) data and enrolled PD patients with comprehensive baseline and 5-year follow-up time-point clinical data. Participants were categorized based on FIB-4 levels to assess the association between FIB-4 scores and various clinical scales, controlling for potential confounders. Differences in the progression of clinical scales over five years were compared using generalized linear mixed models (GLMM).Results: Baseline FIB-4 levels positively correlated to scores of baseline section III of the Unified-Parkinson Disease Rating Scale (UPDRS III) (r = 0.145, p = 0.017), Epworth Sleepiness Scale (EPSS) (r = 0.140, P = 0.022), Hopkins Verbal Learning Test (HVLT)-delayed recall (r = 0.128, P = 0.036) and HVLT-retention (r = 0.128, p = 0.036). GLMM analysis revealed an independent correlation between FIB-4 subgroup*time and several clinical scales including the State-trait Anxiety Inventory (STAI), Symbol Digit Modalities Test (SDMT), Semantic Fluency Test (SF), HVLT-total recall, and HVLT-delayed recall, with the high FIB-4 subgroup exhibiting a greater decline in these scores compared to the low FIB-4 subgroup (all p<0.05).Conclusion: Elevated baseline FIB-4 correlated to more severe baseline daytime sleepiness, motor symptoms, and memory function in PD patients, along with a more rapid decline in cognitive functions such as executive function, information processing ability, and memory. Additionally, a high FIB-4 might confer a protective effect against anxiety.
- 24 January 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1501319
Open AccessBaseline liver fibrosis-4 score correlates to the progression of anxiety and cognitive impairment in patients with Parkinson’s disease
Background: Non-alcoholic fatty liver disease (NAFLD) or liver fibrosis may share similar pathophysiological features with Parkinson’s disease (PD), yet their correlation was unclear. This study aimed to explore their correlation between PD and liver fibrosis using the fibrosis-4 score (FIB-4) as a surrogate marker.Methods: We analyzed Parkinson’s Progression Markers Initiative (PPMI) data and enrolled PD patients with comprehensive baseline and 5-year follow-up time-point clinical data. Participants were categorized based on FIB-4 levels to assess the association between FIB-4 scores and various clinical scales, controlling for potential confounders. Differences in the progression of clinical scales over five years were compared using generalized linear mixed models (GLMM).Results: Baseline FIB-4 levels positively correlated to scores of baseline section III of the Unified-Parkinson Disease Rating Scale (UPDRS III) (r = 0.145, p = 0.017), Epworth Sleepiness Scale (EPSS) (r = 0.140, P = 0.022), Hopkins Verbal Learning Test (HVLT)-delayed recall (r = 0.128, P = 0.036) and HVLT-retention (r = 0.128, p = 0.036). GLMM analysis revealed an independent correlation between FIB-4 subgroup*time and several clinical scales including the State-trait Anxiety Inventory (STAI), Symbol Digit Modalities Test (SDMT), Semantic Fluency Test (SF), HVLT-total recall, and HVLT-delayed recall, with the high FIB-4 subgroup exhibiting a greater decline in these scores compared to the low FIB-4 subgroup (all p<0.05).Conclusion: Elevated baseline FIB-4 correlated to more severe baseline daytime sleepiness, motor symptoms, and memory function in PD patients, along with a more rapid decline in cognitive functions such as executive function, information processing ability, and memory. Additionally, a high FIB-4 might confer a protective effect against anxiety.
- Open Access
- 22 November 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1476701
Total burden of cerebral small vessel disease predict subjective cognitive decline in patients with Parkinson’s disease
Introduction: This study investigates the correlation between the total burden of Cerebral Small Vessel Disease (CSVD) and Subjective Cognitive Decline (SCD) in patients with Parkinson’s disease (PD).Methods: A cross-sectional design was employed, involving 422 patients with PD. Demographic and clinical data were collected. Brain magnetic resonance imaging (MRI) was conducted to identify CSVD markers. SCD was assessed using the Cognitive Complaints Inventory (CCI).Results: Logistic regression analyses revealed that the total burden of CSVD and specific imaging markers, including Deep White Matter Hyperintensities (DWMH), Periventricular Hyperintensities (PVH), and Enlarged Perivascular Spaces (EPVS), were significant predictors of SCD. The total burden of CSVD demonstrated the highest predictive accuracy for SCD in PD patients.Discussion: The findings suggest that the total burden of CSVD, as measured by MRI, could serve as a potential biomarker for early identification of cognitive decline in PD, highlighting the importance of considering vascular factors in the early detection of cognitive changes in PD.
- 22 November 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1476701
Open AccessTotal burden of cerebral small vessel disease predict subjective cognitive decline in patients with Parkinson’s disease
Introduction: This study investigates the correlation between the total burden of Cerebral Small Vessel Disease (CSVD) and Subjective Cognitive Decline (SCD) in patients with Parkinson’s disease (PD).Methods: A cross-sectional design was employed, involving 422 patients with PD. Demographic and clinical data were collected. Brain magnetic resonance imaging (MRI) was conducted to identify CSVD markers. SCD was assessed using the Cognitive Complaints Inventory (CCI).Results: Logistic regression analyses revealed that the total burden of CSVD and specific imaging markers, including Deep White Matter Hyperintensities (DWMH), Periventricular Hyperintensities (PVH), and Enlarged Perivascular Spaces (EPVS), were significant predictors of SCD. The total burden of CSVD demonstrated the highest predictive accuracy for SCD in PD patients.Discussion: The findings suggest that the total burden of CSVD, as measured by MRI, could serve as a potential biomarker for early identification of cognitive decline in PD, highlighting the importance of considering vascular factors in the early detection of cognitive changes in PD.
- Open Access
- 20 May 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (10) , 8810-8821
Systemic immune-inflammation index upon admission correlates to post-stroke cognitive impairment in patients with acute ischemic stroke
Background: The purpose of this prospective study was to evaluate the association of systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI), with PSCI in patients with acute ischemic stroke (AIS). Methods: First-onset AIS patients were consecutively included from January 1, 2022 to March 1, 2023. The baseline information was collected at admission. Fasting blood was drawn the next morning. Cognitive function was assessed by the Montreal Cognitive Assessment (MoCA) 3 months after onset. Logistic regression analysis was performed to explore the correlation between SII, SIRI, and PSCI. Receiver operating characteristic (ROC) was conducted to evaluate the predictive ability of SII. Results: 332 participants were recruited, and 193 developed PSCI. Compared with patients without PSCI, the patients with PSCI had higher SII (587.75 (337.42, 988.95) vs. 345.66 (248.44, 572.89), P<0.001) and SIRI (1.59 (0.95, 2.84) vs. 1.02 (0.63, 1.55), P=0.007). SII and SIRI negatively correlated with MoCA scores (both P<0.05). The multivariable logistic regression analysis indicated that SII was independently associated with PSCI (P<0.001), while SIRI was not. The optimal cutoff for SII to predict PSCI was 676.83×109/L. Conclusions: A higher level of SII upon admission was independently correlated to PSCI three months later in AIS patients.
- 20 May 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (10) , 8810-8821
Open AccessSystemic immune-inflammation index upon admission correlates to post-stroke cognitive impairment in patients with acute ischemic stroke
Background: The purpose of this prospective study was to evaluate the association of systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI), with PSCI in patients with acute ischemic stroke (AIS). Methods: First-onset AIS patients were consecutively included from January 1, 2022 to March 1, 2023. The baseline information was collected at admission. Fasting blood was drawn the next morning. Cognitive function was assessed by the Montreal Cognitive Assessment (MoCA) 3 months after onset. Logistic regression analysis was performed to explore the correlation between SII, SIRI, and PSCI. Receiver operating characteristic (ROC) was conducted to evaluate the predictive ability of SII. Results: 332 participants were recruited, and 193 developed PSCI. Compared with patients without PSCI, the patients with PSCI had higher SII (587.75 (337.42, 988.95) vs. 345.66 (248.44, 572.89), P<0.001) and SIRI (1.59 (0.95, 2.84) vs. 1.02 (0.63, 1.55), P=0.007). SII and SIRI negatively correlated with MoCA scores (both P<0.05). The multivariable logistic regression analysis indicated that SII was independently associated with PSCI (P<0.001), while SIRI was not. The optimal cutoff for SII to predict PSCI was 676.83×109/L. Conclusions: A higher level of SII upon admission was independently correlated to PSCI three months later in AIS patients.
- Open Access
- 1 January 2023
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 19, 209-217
Correlation Between Cognitive Impairment and Homocysteine and S100B Protein in Patients with Progressive Ischemic Stroke
Purpose: This study aimed to investigate the relationship between cognitive impairment and homocysteine (Hcy) and S100B protein in patients with progressive ischemic stroke (PIS). Patients and Methods: A total of 158 patients with PIS hospitalized in the Department of Neurology in Taixing People’s Hospital from January 2020 to March 2022 were enrolled in the study. After 90 days of follow-up, the patients were divided into two groups according to the MoCA score— 99 cases with cognitive impairment group (observation group) and 59 cases with cognitive normal group (control group). Causal diagram was drawn to assess the association between risk factors and PIS with observation group. The risk factors indicators of cognitive impairment in patients with PIS were screened. The related predictive indicators were screened by multivariate logistic regression analysis, and Pearson correlation analysis. The predictive value was analyzed by Receiver Operating Characteristic (ROC) curve. Results: Multivariate logistic regression analysis showed that age, hypertension, lesion position, Hcy and S100B protein were related risk factors for cognitive impairment in patients with PIS. Pearson correlation analysis was conducted between Hcy and S100 B protein and MoCA score, and revealed that Hcy and S100 B protein were negatively correlated with MoCA score. ROC curve analysis showed that the Area Under the Curve (AUC) of S100 B protein and Hcy in identifying cognitive impairment after PIS was 0.709 and 0.673, respectively, and the combined AUC of Hcy and S100B protein in predicting cognitive impairment after PIS was 0.739. Conclusion: Hcy and S100B protein are related risk factors for cognitive impairment in patients with PIS, and may be used as in a prediction model to predict cognitive impairment after PIS in the future.
- 1 January 2023
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 19, 209-217
Open AccessCorrelation Between Cognitive Impairment and Homocysteine and S100B Protein in Patients with Progressive Ischemic Stroke
Purpose: This study aimed to investigate the relationship between cognitive impairment and homocysteine (Hcy) and S100B protein in patients with progressive ischemic stroke (PIS). Patients and Methods: A total of 158 patients with PIS hospitalized in the Department of Neurology in Taixing People’s Hospital from January 2020 to March 2022 were enrolled in the study. After 90 days of follow-up, the patients were divided into two groups according to the MoCA score— 99 cases with cognitive impairment group (observation group) and 59 cases with cognitive normal group (control group). Causal diagram was drawn to assess the association between risk factors and PIS with observation group. The risk factors indicators of cognitive impairment in patients with PIS were screened. The related predictive indicators were screened by multivariate logistic regression analysis, and Pearson correlation analysis. The predictive value was analyzed by Receiver Operating Characteristic (ROC) curve. Results: Multivariate logistic regression analysis showed that age, hypertension, lesion position, Hcy and S100B protein were related risk factors for cognitive impairment in patients with PIS. Pearson correlation analysis was conducted between Hcy and S100 B protein and MoCA score, and revealed that Hcy and S100 B protein were negatively correlated with MoCA score. ROC curve analysis showed that the Area Under the Curve (AUC) of S100 B protein and Hcy in identifying cognitive impairment after PIS was 0.709 and 0.673, respectively, and the combined AUC of Hcy and S100B protein in predicting cognitive impairment after PIS was 0.739. Conclusion: Hcy and S100B protein are related risk factors for cognitive impairment in patients with PIS, and may be used as in a prediction model to predict cognitive impairment after PIS in the future.
- 4 August 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (10) , 6307-6320
miR-383-5p Regulated by the Transcription Factor CTCF Affects Neuronal Impairment in Cerebral Ischemia by Mediating Deacetylase HDAC9 Activity
Stroke, the leading cause of long-term disability worldwide, is caused by the blockage or hemorage of cerebral arteries. The resultant cerebral ischemia causes local neuronal death and brain injury. Histone deacetylase 9 (HDAC9) has been reported to be elevated in ischemic brain injury, but its mechanism in stroke is still enigmatic. The present study aimed to unveil the manner of regulation of HDAC9 expression and the effect of HDAC9 activation on neuronal function in cerebral ischemia. MicroRNAs (miRNAs) targeting HDAC9 were predicted utilizing bioinformatics analysis. We then constructed the oxygen glucose deprivation (OGD) cell model and the middle cerebral artery occlusion (MCAO) rat model, and elucidated the expression of CCCTC binding factor (CTCF)/miR-383-5p/HDAC9. Targeting between miR-383-5p and HDAC9 was verified by dual-luciferase reporter assay and RNAi. After conducting an overexpression/knockdown assay, we assessed neuronal impairment and brain injury. We found that CTCF inhibited miR-383-5p expression via its enrichment in the promoter region of miR-383-5p, whereas the miR-383-5p targeted and inhibited HDAC9 expression. In the OGD model and the MCAO model, we confirmed that elevation of HDAC9 regulated by the CTCF/miR-383-5p/HDAC9 pathway mediated apoptosis induced by endoplasmic reticulum stress, while reduction of HDAC9 alleviated apoptosis and the symptoms of cerebral infarction in MCAO rats. Thus, the CTCF/miR-383-5p/HDAC9 pathway may present a target for drug development against ischemic brain injury.
- 4 August 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (10) , 6307-6320
miR-383-5p Regulated by the Transcription Factor CTCF Affects Neuronal Impairment in Cerebral Ischemia by Mediating Deacetylase HDAC9 Activity
Stroke, the leading cause of long-term disability worldwide, is caused by the blockage or hemorage of cerebral arteries. The resultant cerebral ischemia causes local neuronal death and brain injury. Histone deacetylase 9 (HDAC9) has been reported to be elevated in ischemic brain injury, but its mechanism in stroke is still enigmatic. The present study aimed to unveil the manner of regulation of HDAC9 expression and the effect of HDAC9 activation on neuronal function in cerebral ischemia. MicroRNAs (miRNAs) targeting HDAC9 were predicted utilizing bioinformatics analysis. We then constructed the oxygen glucose deprivation (OGD) cell model and the middle cerebral artery occlusion (MCAO) rat model, and elucidated the expression of CCCTC binding factor (CTCF)/miR-383-5p/HDAC9. Targeting between miR-383-5p and HDAC9 was verified by dual-luciferase reporter assay and RNAi. After conducting an overexpression/knockdown assay, we assessed neuronal impairment and brain injury. We found that CTCF inhibited miR-383-5p expression via its enrichment in the promoter region of miR-383-5p, whereas the miR-383-5p targeted and inhibited HDAC9 expression. In the OGD model and the MCAO model, we confirmed that elevation of HDAC9 regulated by the CTCF/miR-383-5p/HDAC9 pathway mediated apoptosis induced by endoplasmic reticulum stress, while reduction of HDAC9 alleviated apoptosis and the symptoms of cerebral infarction in MCAO rats. Thus, the CTCF/miR-383-5p/HDAC9 pathway may present a target for drug development against ischemic brain injury.
- 15 July 2022
- Vol. 14 (7) , 5077-5087
Effect of cognitive behavioral intervention on anxiety, depression, and quality of life in patients with epilepsy
Objective: This study aimed to investigate the effect of cognitive behavioral therapy (CBT) on quality of life, anxiety, and depression in patients with epilepsy. Methods: Each study subject was randomly assigned to a CBT (n=46) or control (n=49) group (1:1 ratio), and the first group underwent an 8-week CBT treatment. Anxiety, depression, and quality of life (QOLIE-31) were assessed at both baseline and endpoint using the Self-Rating Anxiety Scale (SAS), Hamilton Depression Scale (HDMA) and quality of life in Epilepsy-31 (QOLIE-31) scales. The statistical analyses included between-and within-group comparisons of the effects of CBT on these measures and associations with demographic and clinical variables. Results: No differences were found between variables at baseline (P>0.05). The repeated-measures analyses found that CBT group had greater improvement in depression score compared to the control group (P<0.05). The analysis of anxiety score showed that compared to the control group, CBT intervention had no statistical significance in the total anxiety population. However, the CBT intervention decreased anxiety in women and Combined-drug group (P<0.05). The CBT group had greater improvement in overall score, medication effect, and seizure worry score than the control group (P<0.05). Stratified analysis found total and medication effects score of CBT intervention group for the combined-drug group were higher than those of the single drug group (P<0.05). Conclusion: Increases in overall scores, seizure worry, cognitive functioning, and medication effect were better in the CBT group. CBT can improve anxiety, depression, and quality of life in patients with epilepsy. Women and combined-drug patients with epilepsy benefit most from CBT.
- 15 July 2022
- Vol. 14 (7) , 5077-5087
Effect of cognitive behavioral intervention on anxiety, depression, and quality of life in patients with epilepsy
Objective: This study aimed to investigate the effect of cognitive behavioral therapy (CBT) on quality of life, anxiety, and depression in patients with epilepsy. Methods: Each study subject was randomly assigned to a CBT (n=46) or control (n=49) group (1:1 ratio), and the first group underwent an 8-week CBT treatment. Anxiety, depression, and quality of life (QOLIE-31) were assessed at both baseline and endpoint using the Self-Rating Anxiety Scale (SAS), Hamilton Depression Scale (HDMA) and quality of life in Epilepsy-31 (QOLIE-31) scales. The statistical analyses included between-and within-group comparisons of the effects of CBT on these measures and associations with demographic and clinical variables. Results: No differences were found between variables at baseline (P>0.05). The repeated-measures analyses found that CBT group had greater improvement in depression score compared to the control group (P<0.05). The analysis of anxiety score showed that compared to the control group, CBT intervention had no statistical significance in the total anxiety population. However, the CBT intervention decreased anxiety in women and Combined-drug group (P<0.05). The CBT group had greater improvement in overall score, medication effect, and seizure worry score than the control group (P<0.05). Stratified analysis found total and medication effects score of CBT intervention group for the combined-drug group were higher than those of the single drug group (P<0.05). Conclusion: Increases in overall scores, seizure worry, cognitive functioning, and medication effect were better in the CBT group. CBT can improve anxiety, depression, and quality of life in patients with epilepsy. Women and combined-drug patients with epilepsy benefit most from CBT.
- Open Access
- 1 May 2022
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 17, 745-753
Level of LncRNA GAS5 and Hippocampal Volume are Associated with the Progression of Alzheimer’s Disease
Purpose: We evaluated the diagnostic value of long non-coding RNA growth arrest-specific transcript 5 (GAS5) and its relationship with hippocampal volume in Alzheimer’s disease (AD). Patients and Methods: One hundred and eight patients with AD and 83 healthy controls were included, and demographic data, biochemical parameters, GAS5 levels, and hippocampal volume were recorded. Chi-squared tests or independent sample t-tests were used to compare the baseline characteristics, relative expression of GAS5, and hippocampal volume. Correlations between variables were determined using Spearman’s rank correlation test. Receiver operating characteristic (ROC) curves were generated to compare the diagnostic value of GAS5 and total hippocampal volume in AD. Results: The levels of GAS5 were significantly upregulated in patients with AD compared with those in controls and were negatively correlated with MMSE score. There were differences in left hippocampal volume, right hippocampal volume, and total hippocampal volume between the two groups. Total hippocampal volume was positively correlated with MMSE score and negatively correlated with GAS5 expression in patients with AD. The area under the curve (AUC) of for GAS5 expression was 0.831, the sensitivity was 61.1%, and the specificity was 95.2%. The AUC of the combined total hippocampal volume was 0.891, the sensitivity was 74.1%, and the specificity was 92.8%. Conclusion: The results suggested that GAS5 may be an excellent indicator of AD progression alone or in combination with hippocampal volume.
- 1 May 2022
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 17, 745-753
Open AccessLevel of LncRNA GAS5 and Hippocampal Volume are Associated with the Progression of Alzheimer’s Disease
Purpose: We evaluated the diagnostic value of long non-coding RNA growth arrest-specific transcript 5 (GAS5) and its relationship with hippocampal volume in Alzheimer’s disease (AD). Patients and Methods: One hundred and eight patients with AD and 83 healthy controls were included, and demographic data, biochemical parameters, GAS5 levels, and hippocampal volume were recorded. Chi-squared tests or independent sample t-tests were used to compare the baseline characteristics, relative expression of GAS5, and hippocampal volume. Correlations between variables were determined using Spearman’s rank correlation test. Receiver operating characteristic (ROC) curves were generated to compare the diagnostic value of GAS5 and total hippocampal volume in AD. Results: The levels of GAS5 were significantly upregulated in patients with AD compared with those in controls and were negatively correlated with MMSE score. There were differences in left hippocampal volume, right hippocampal volume, and total hippocampal volume between the two groups. Total hippocampal volume was positively correlated with MMSE score and negatively correlated with GAS5 expression in patients with AD. The area under the curve (AUC) of for GAS5 expression was 0.831, the sensitivity was 61.1%, and the specificity was 95.2%. The AUC of the combined total hippocampal volume was 0.891, the sensitivity was 74.1%, and the specificity was 92.8%. Conclusion: The results suggested that GAS5 may be an excellent indicator of AD progression alone or in combination with hippocampal volume.